December 7th, 2014
•Emergence of genetic resistance against kinase inhibitor therapy poses significant challenge for effective cancer therapy. Identification and characterization of resistant mutations against a newly developed drug helps in better clinical management and next generation drug design. Here, we describe our protocol for in vitro screening and validation of resistant mutations.
Related Videos
Injection of An. stephensi Embryos to Generate Malaria-resistant Mosquitoes
Application of a C. elegans Dopamine Neuron Degeneration Assay for the Validation of Potential Parkinson's Disease Genes
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Assaying the Kinase Activity of LRRK2 in vitro
Conversion of a Capture ELISA to a Luminex xMAP Assay using a Multiplex Antibody Screening Method
RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes
Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Identification of Kinase-substrate Pairs Using High Throughput Screening
Interactome-Seq: A Protocol for Domainome Library Construction, Validation and Selection by Phage Display and Next Generation Sequencing
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved